Tools
Loperamide
Indications
Loperamide is an over-the-counter oral antidiarrheal agent synthesized in 1969, first used medically in 1976, and became available without a prescription in 1988.[1] Initially, the Federal Drug Administration (FDA) categorized it as a Schedule V drug due to its opioid-like misuse potential.[2]
FDA-Approved Indications
Currently, loperamide has been approved by the FDA to treat various forms of diarrhea and has also been used off-label to treat the adverse effects of chemotherapy resulting in diarrhea. In recent years, there has been an increased interest in the non-medical use of loperamide, ranging from self-management of opioid withdrawal symptoms to a means to induce euphoria (ie, getting high). Recently, a new syndrome termed loperamide-induced cardiotoxicity has come to light.[3] Patients can present with different forms of potentially life-threatening dysrhythmias when using loperamide in toxic doses.
Medical Use: The FDA has approved loperamide for treating various forms of diarrhea, including traveler’s diarrhea, irritable bowel syndrome associated with chronic diarrhea, and acute nonspecific diarrhea in patients 2 and older, in addition to the indication for reducing ileostomy output.[4][5]
Off-Label Uses
The off-label uses include the management of chemotherapy-related diarrhea. According to ASCO (American Society of Clinical Oncology) guidelines, loperamide may be used for diarrhea associated with immune checkpoint inhibitor (ICPi) therapy; however, infection and colitis must be ruled out before initiating loperamide.[6]
Illicit Drug Use and Self-Medication Use: In recent years, there has been a noticeable incline in the use and abuse of loperamide as a means of self-management of opioid withdrawal and an inexpensive method to induce euphoria, ie, to achieve a euphoric state. Vakkalanka et al found a 91% increase in reported loperamide exposures, including 8 deaths, from 2010 to 2015 across Poison Control Centers in the United States.[7]
Individuals have used loperamide as a means to self-medicate to decrease the withdrawal adverse effects of opioid dependence or slow the tapering process. Recently, high-dose loperamide has shown promise for such use.[8]
Mechanism of Action
Register For Free And Read The Full Article
Search engine and full access to all medical articles- 10 free questions in your specialty
- Free CME/CE Activities
- Free daily question in your email
- Save favorite articles to your dashboard
- Emails offering discounts
Learn more about a Subscription to StatPearls Point-of-Care
Mechanism of Action
Loperamide is a lipophilic synthetic phenylpiperidine opioid and a μ-receptor agonist.[4][9] At therapeutic doses, loperamide acts on the μ-opioid receptors directly on the circular and longitudinal intestinal muscles to decrease transition time, inhibit peristalsis electrolyte loss, and increase rectal tone. However, because loperamide is a substrate for P-glycoprotein at higher doses, P-glycoprotein is inhibited, allowing loperamide to cross the blood-brain barrier and act on the central nervous system, producing central opioid effects and toxicity.[10]
Loperamide was also found to inhibit both the Na+ gated cardiac channels, which prolongs the QRS complex, and the hERG channel, which increases the QTc interval.[11] QRS and QTc prolongation can cause ventricular dysrhythmias, monomorphic and polymorphic ventricular tachycardia, torsade de pointes, ventricular fibrillation, Brugada syndrome, cardiac arrest, and death.
(a) Pharmacokinetics
(i) Absorption: The peak plasma time is 4 to 5 hours, with a half-life of 7 to 19 hours.[12] Loperamide has a low bioavailability (<1%) due to the first-pass metabolism.
(ii) Distribution: Loperamide has high protein binding and a large volume of distribution.
(iii) Metabolism: Loperamide is extracted in the GI tract and metabolized in the liver by the cytochrome P450 pathway. The drug is metabolized in the liver via CYP2C8 and CYP3A4 to desmethyl-loperamide.[3] This pathway allows for decreased gastrointestinal uptake and, thus, enhanced elimination through bile excretion. At recommended doses, almost no active loperamide is present in the systemic circulation.
(iv) Elimination: The elimination half-life of loperamide varies between 9.1 to 14.4 hours. The excretion of loperamide and its metabolites is predominantly through feces.
Administration
Available Dosage Forms and Strengths
Loperamide is available in different formulations, most commonly as tablets, capsules, and orodispersible tablets that melt on the tongue. Loperamide is available as 2 mg tablets, capsules, and oral solutions of 1 mg/7.5 mL and 2 mg/15 mL strengths. The oral solution should be shaken well before being administered to the patient. Consider administering loperamide with plenty of fluids to prevent dehydration. A combination of loperamide 2 mg and simethicone 125 mg is also available for the symptomatic relief of diarrhea plus bloating.
Adult Dosing
The usual initial recommended dose for acute diarrhea, such as traveler’s diarrhea, is a 4 mg starting dose, followed by 2 mg after each unformed stool. The total dose is not to exceed 8 mg daily for over-the-counter use and 16 mg daily for prescription use. For chronic use, the suggested dose is 2 mg twice daily. Consider administering loperamide 30 minutes before food 4 times daily for patients with chemotherapy-induced diarrhea to slow colic reflex.
According to the Infectious Disease Society of America, clinicians can use loperamide as adjuvant therapy with close monitoring and concomitant antibiotics in patients with suspected or known dysentery.[13] Loperamide is usually avoided in patients with C difficile infection; however, some experts approve using close monitoring and concomitant antibiotics if the patient has significant fluid losses and no contraindications (ileus/colonic distention).[14]
Chemotherapy-induced diarrhea (off-label use): Initially administer 4 mg, followed by 2 mg every 2 to 4 hours or after each loose stool. For diarrhea persisting for more than 24 hours, administer 2 mg every 2 hours (or 4 mg every 4 hours). Continue until 12 hours have passed without a loose bowel movement. Experts consider recommending alternative therapy for diarrhea persisting more than 48 hours, and doses of more than 16 mg per day might not provide benefit.[15] Loperamide is used to prevent diarrhea caused by neratinib and irinotecan.
Specific Patient Populations
Hepatic impairment: No dose adjustment of loperamide for hepatic impairment is provided in the product labeling; use caution in patients with liver impairment.
Renal impairment: According to manufacturer labeling, no dose adjustment is required in patients with mild to severe renal impairment. In addition, since it is highly protein-bound, no dose adjustment is needed for dialysis.
Pregnancy considerations: There are no adverse effects observed in animal studies. There is a lack of data on loperamide use in pregnant women, and the information is conflicting.[16] For managing acute diarrhea in pregnancy, some experts recommend only oral rehydration and dietary modifications. Loperamide is also recommended in the lowest possible amount if the patient’s symptoms are disabling.[17]
Breastfeeding considerations: Loperamide may be excreted into breast milk. The study on loperamide oxide (prodrug of loperamide) was conducted in breastfeeding women and found variable concentrations of loperamide and loperamide oxide in breast milk.[18] Manufacturers recommend against breastfeeding. Furthermore, loperamide is contraindicated in children younger than 2.
Pediatric patients: According to the Infectious Disease Society of America, loperamide is not recommended to manage infectious diarrhea in pediatric patients.[19] Use a minimum effective dose for the possible shortest duration. Loperamide is not recommended for children younger than 2. Consider calculating the dose based on weight:
- 13 kg to 21 kg: 1 mg when first loose stool followed by 1 mg per dose after each subsequent unformed stool, but not more than 3 mg daily.
- 21 kg to 27 kg: 2 mg when first loose stool followed by 1 mg per dose after each subsequent unformed stool, but not more than 4 mg daily.
- 27.1 kg to 43 kg: 2 mg when first loose stool followed by 1 mg per dose after each subsequent unformed stool, but not more than 6 mg daily.
- Children 12 years and older: 4 mg when first loose stool, followed by 2 mg per dose after each subsequent unformed stool, but not more than 8 mg daily.
Older patients: Use with caution in older patients due to the risk of paralytic ileus.[20]
Adverse Effects
Common Adverse Drug Reactions
- Dry mouth
- Flatulence
- Abdominal cramps
- Nausea
- Ileus
- Constipation
- Urinary retention
- Dizziness
- Drowsiness [4]
Serious Adverse Drug Reactions
- Toxic megacolon
- Necrotizing enterocolitis
- Stevens-Johnson syndrome
- Toxic epidermal necrolysis [8]
- Syncope
- QT/QTc interval prolongation, torsades de pointes, ventricular tachycardia (VT) [21]
- VT storm: 3 or more episodes of VT within 24 hours [22]
- Other ventricular arrhythmias and cardiac arrest [23]
Drug-Drug Interactions
Loperamide is extracted in the liver and metabolized primarily by CYP3A4, a cytochrome P450 enzyme.[3] The drug is then conjugated and excreted into the bile. Loperamide has significant drug-drug interactions, and it is essential to check concomitant medicines before prescribing loperamide. Patients with hepatic impairment can have changed first-pass metabolism amounts, leading to CNS adverse reactions. Concomitant administration of lonafarnib may increase the plasma concentration of loperamide. Initially, do not use more than 1 mg of loperamide daily when using loperamide with lonafarnib. If clinically indicated, the dose of loperamide can be cautiously increased.
Loperamide is a substrate of P-glycoprotein; it can interact with inducers of P-glycoprotein like carbamazepine, mitotane, phenytoin, and rifampicin. Similarly, loperamide can interact with P-glycoprotein inhibitors like amiodarone, carvedilol, ritonavir, quinidine, itraconazole, verapamil, clarithromycin, and ranolazine. Use with caution.[24]
Contraindications
Loperamide is contraindicated in patients younger than 2 and patients of any age with acute ulcerative colitis, bloody diarrhea, and diarrhea associated with bacterial infections.[25] Hypersensitivity to loperamide or any excipients is a contraindication to using loperamide.[26] A case report of fatal anaphylaxis has been reported.[27]
Box Warning
Loperamide has a boxed warning for torsades de pointes and sudden death when used in higher-than-recommended doses.[28]
Monitoring
Currently, loperamide remains available over the counter in pharmacies with restricted access but without a prescription. Patients should understand the maximum recommended daily dose when dispensing loperamide for FDA-approved or off-label indications. The clinical status of patients and loperamide efficacy should be monitored, in addition to the number of loose stools after each dose. When used in high doses, clinicians should routinely obtain an ECG and assess for signs/symptoms of CNS disturbances and respiratory depression.[29]
Toxicity
When loperamide is taken in large doses or with other drugs that may alter its pharmacokinetic effects, such as p-glycoprotein inhibitors, loperamide produces opioid-like symptoms. These include a sensation of euphoria, miosis, central nervous system depression, and respiratory depression. Treatment of loperamide overdose and toxicity is primarily supportive. Naloxone, including an intranasal naloxone bolus, intravenous naloxone bolus, or naloxone infusion, may be used in patients with respiratory depression.[30] As naloxone has a shorter half-life than loperamide, patients should be observed for at least 24 hours after the last naloxone administration to ensure they do not deteriorate clinically.
In large quantities, loperamide can cause systemic effects similar to opioid toxicity (central nervous system depression, respiratory depression) and lethal cardiac conduction abnormalities.[3] The patient should be on a cardiac monitor, and an ECG should be obtained. If QRS widening is present, sodium bicarbonate may be given and repeated in boluses or as an infusion.[31]
If the patient exhibits signs of QTc prolongation (QTc is considered prolonged if greater than 450 ms in males and 470 ms in females), electrolyte abnormalities (magnesium, potassium, phosphate) should be corrected, and isoproterenol or transcutaneous pacing may be an option.[32] Cardiac arrest is manageable using standard ACLS protocols.
Enhancing Healthcare Team Outcomes
Healthcare providers widely prescribe loperamide for different types of diarrhea. Even though loperamide is available as an over-the-counter medication, its use still requires the attention and oversight of an interprofessional healthcare team. Pharmacists and clinicians should check the potential for abuse and educate the patient about its potential toxicity in higher than recommended doses. Nurses can also provide monitoring and counseling in this area.
In September 2019, the FDA approved new package size limitations and unit-dose packaging for certain over-the-counter loperamide products to improve patient safety. When prescribing or recommending loperamide, the nurse and pharmacist should reiterate all safety and dosing issues to ensure proper medication use and optimize patient safety, as patients may think loperamide has no potential for misuse due to its OTC availability.
In an overdose, an emergency medicine clinician should rapidly stabilize the patient. A toxicologist consult is necessary for a complicated overdose. An interprofessional team approach and open communication between physicians, advanced practice practitioners, nurses, pharmacists, toxicologists, and specialists can achieve optimal patient outcomes with fewer adverse effects.
References
Kaplan MA, Prior MJ, McKonly KI, DuPont HL, Temple AR, Nelson EB. A multicenter randomized controlled trial of a liquid loperamide product versus placebo in the treatment of acute diarrhea in children. Clinical pediatrics. 1999 Oct:38(10):579-91 [PubMed PMID: 10544864]
Level 1 (high-level) evidenceMacDonald R, Heiner J, Villarreal J, Strote J. Loperamide dependence and abuse. BMJ case reports. 2015 May 2:2015():. doi: 10.1136/bcr-2015-209705. Epub 2015 May 2 [PubMed PMID: 25935922]
Level 3 (low-level) evidenceWu PE, Juurlink DN. Clinical Review: Loperamide Toxicity. Annals of emergency medicine. 2017 Aug:70(2):245-252. doi: 10.1016/j.annemergmed.2017.04.008. Epub 2017 May 13 [PubMed PMID: 28506439]
Regnard C, Twycross R, Mihalyo M, Wilcock A. Loperamide. Journal of pain and symptom management. 2011 Aug:42(2):319-23. doi: 10.1016/j.jpainsymman.2011.06.001. Epub 2011 Jun 23 [PubMed PMID: 21703817]
Lembo A, Sultan S, Chang L, Heidelbaugh JJ, Smalley W, Verne GN. AGA Clinical Practice Guideline on the Pharmacological Management of Irritable Bowel Syndrome With Diarrhea. Gastroenterology. 2022 Jul:163(1):137-151. doi: 10.1053/j.gastro.2022.04.017. Epub [PubMed PMID: 35738725]
Level 1 (high-level) evidenceSchneider BJ, Naidoo J, Santomasso BD, Lacchetti C, Adkins S, Anadkat M, Atkins MB, Brassil KJ, Caterino JM, Chau I, Davies MJ, Ernstoff MS, Fecher L, Ghosh M, Jaiyesimi I, Mammen JS, Naing A, Nastoupil LJ, Phillips T, Porter LD, Reichner CA, Seigel C, Song JM, Spira A, Suarez-Almazor M, Swami U, Thompson JA, Vikas P, Wang Y, Weber JS, Funchain P, Bollin K. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2021 Dec 20:39(36):4073-4126. doi: 10.1200/JCO.21.01440. Epub 2021 Nov 1 [PubMed PMID: 34724392]
Vakkalanka JP, Charlton NP, Holstege CP. Epidemiologic Trends in Loperamide Abuse and Misuse. Annals of emergency medicine. 2017 Jan:69(1):73-78. doi: 10.1016/j.annemergmed.2016.08.444. Epub 2016 Nov 4 [PubMed PMID: 27823872]
Litovitz T, Clancy C, Korberly B, Temple AR, Mann KV. Surveillance of loperamide ingestions: an analysis of 216 poison center reports. Journal of toxicology. Clinical toxicology. 1997:35(1):11-9 [PubMed PMID: 9022646]
Level 3 (low-level) evidenceKillinger JM, Weintraub HS, Fuller BL. Human pharmacokinetics and comparative bioavailability of loperamide hydrochloride. Journal of clinical pharmacology. 1979 Apr:19(4):211-8 [PubMed PMID: 438356]
Level 1 (high-level) evidenceVandenbossche J, Huisman M, Xu Y, Sanderson-Bongiovanni D, Soons P. Loperamide and P-glycoprotein inhibition: assessment of the clinical relevance. The Journal of pharmacy and pharmacology. 2010 Apr:62(4):401-12. doi: 10.1211/jpp.62.04.0001. Epub [PubMed PMID: 20604828]
Kang J, Compton DR, Vaz RJ, Rampe D. Proarrhythmic mechanisms of the common anti-diarrheal medication loperamide: revelations from the opioid abuse epidemic. Naunyn-Schmiedeberg's archives of pharmacology. 2016 Oct:389(10):1133-7. doi: 10.1007/s00210-016-1286-7. Epub 2016 Aug 16 [PubMed PMID: 27530870]
Heel RC, Brogden RN, Speight TM, Avery GS. Loperamide: a review of its pharmacological properties and therapeutic efficacy in diarrhoea. Drugs. 1978 Jan:15(1):33-52 [PubMed PMID: 342229]
Level 3 (low-level) evidenceHill DR, Ericsson CD, Pearson RD, Keystone JS, Freedman DO, Kozarsky PE, DuPont HL, Bia FJ, Fischer PR, Ryan ET, Infectious Diseases Society of America. The practice of travel medicine: guidelines by the Infectious Diseases Society of America. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2006 Dec 15:43(12):1499-539 [PubMed PMID: 17109284]
McDonald LC, Gerding DN, Johnson S, Bakken JS, Carroll KC, Coffin SE, Dubberke ER, Garey KW, Gould CV, Kelly C, Loo V, Shaklee Sammons J, Sandora TJ, Wilcox MH. Clinical Practice Guidelines for Clostridium difficile Infection in Adults and Children: 2017 Update by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA). Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2018 Mar 19:66(7):e1-e48. doi: 10.1093/cid/cix1085. Epub [PubMed PMID: 29462280]
Level 1 (high-level) evidenceAndreyev J, Ross P, Donnellan C, Lennan E, Leonard P, Waters C, Wedlake L, Bridgewater J, Glynne-Jones R, Allum W, Chau I, Wilson R, Ferry D. Guidance on the management of diarrhoea during cancer chemotherapy. The Lancet. Oncology. 2014 Sep:15(10):e447-60. doi: 10.1016/S1470-2045(14)70006-3. Epub [PubMed PMID: 25186048]
Einarson A, Mastroiacovo P, Arnon J, Ornoy A, Addis A, Malm H, Koren G. Prospective, controlled, multicentre study of loperamide in pregnancy. Canadian journal of gastroenterology = Journal canadien de gastroenterologie. 2000 Mar:14(3):185-7 [PubMed PMID: 10758415]
Level 1 (high-level) evidenceWald A. Constipation, diarrhea, and symptomatic hemorrhoids during pregnancy. Gastroenterology clinics of North America. 2003 Mar:32(1):309-22, vii [PubMed PMID: 12635420]
Nikodem VC, Hofmeyr GJ. Secretion of the antidiarrhoeal agent loperamide oxide in breast milk. European journal of clinical pharmacology. 1992:42(6):695-6 [PubMed PMID: 1623917]
Level 3 (low-level) evidenceShane AL, Mody RK, Crump JA, Tarr PI, Steiner TS, Kotloff K, Langley JM, Wanke C, Warren CA, Cheng AC, Cantey J, Pickering LK. 2017 Infectious Diseases Society of America Clinical Practice Guidelines for the Diagnosis and Management of Infectious Diarrhea. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2017 Nov 29:65(12):e45-e80. doi: 10.1093/cid/cix669. Epub [PubMed PMID: 29053792]
Level 1 (high-level) evidenceZaniello B, Phillips-Caesar E. Over-the-counter medication overuse and bowel obstruction. Journal of the American Geriatrics Society. 2014 Feb:62(2):400-2. doi: 10.1111/jgs.12641. Epub [PubMed PMID: 24521380]
Level 3 (low-level) evidenceTeigeler T, Stahura H, Alimohammad R, Kalahasty G, Koneru JN, Ellenbogen M, Ellenbogen KA, Padala SK. Electrocardiographic changes in loperamide toxicity: Case report and review of literature. Journal of cardiovascular electrophysiology. 2019 Nov:30(11):2618-2626. doi: 10.1111/jce.14129. Epub 2019 Aug 29 [PubMed PMID: 31432581]
Level 3 (low-level) evidenceGiesing W, Koester C, Al-Akchar M, Kulkarni A, Labedi M. Loperamide-Induced Ventricular Tachycardia Storm. Avicenna journal of medicine. 2022 Apr:12(2):93-96. doi: 10.1055/s-0042-1749628. Epub 2022 Jun 22 [PubMed PMID: 35833161]
Spinner HL, Lonardo NW, Mulamalla R, Stehlik J. Ventricular tachycardia associated with high-dose chronic loperamide use. Pharmacotherapy. 2015 Feb:35(2):234-8. doi: 10.1002/phar.1540. Epub 2015 Feb 3 [PubMed PMID: 25645123]
Level 3 (low-level) evidenceAsiimwe IG, Pirmohamed M. Drug-Drug-Gene Interactions in Cardiovascular Medicine. Pharmacogenomics and personalized medicine. 2022:15():879-911. doi: 10.2147/PGPM.S338601. Epub 2022 Nov 2 [PubMed PMID: 36353710]
Li ST, Grossman DC, Cummings P. Loperamide therapy for acute diarrhea in children: systematic review and meta-analysis. PLoS medicine. 2007 Mar 27:4(3):e98 [PubMed PMID: 17388664]
Level 1 (high-level) evidenceNahas O, Alary V, Chiriac AM, Philibert C, Demoly P, Hillaire-Buys D. Delayed hypersensitivity reaction to loperamide: An intriguing case report with positive challenge test. Allergology international : official journal of the Japanese Society of Allergology. 2017 Jan:66(1):139-140. doi: 10.1016/j.alit.2016.05.011. Epub 2016 Jun 28 [PubMed PMID: 27363731]
Level 3 (low-level) evidenceSrinivasa MR, Phelan C. Death due to anaphylactic shock after ingestion of Imodium instants (Loperamide). Allergy. 2007 Aug:62(8):965-6 [PubMed PMID: 17620078]
Level 3 (low-level) evidenceKapaganti S, Anwar Ansari S, Saba R, Elkhouly A, Hassib M. A Rare Case of Loperamide-Induced Cardiac Arrest. Cureus. 2020 Jul 26:12(7):e9396. doi: 10.7759/cureus.9396. Epub 2020 Jul 26 [PubMed PMID: 32864227]
Level 3 (low-level) evidenceEggleston W, Clark KH, Marraffa JM. Loperamide Abuse Associated With Cardiac Dysrhythmia and Death. Annals of emergency medicine. 2017 Jan:69(1):83-86. doi: 10.1016/j.annemergmed.2016.03.047. Epub 2016 Apr 29 [PubMed PMID: 27140747]
Eggleston W, Palmer R, Dubé PA, Thornton S, Stolbach A, Calello DP, Marraffa JM. Loperamide toxicity: recommendations for patient monitoring and management. Clinical toxicology (Philadelphia, Pa.). 2020 May:58(5):355-359. doi: 10.1080/15563650.2019.1681443. Epub 2019 Nov 4 [PubMed PMID: 31684751]
Lasoff DR, Schneir A. Ventricular Dysrhythmias from Loperamide Misuse. The Journal of emergency medicine. 2016 Mar:50(3):508-9. doi: 10.1016/j.jemermed.2015.11.017. Epub 2016 Jan 19 [PubMed PMID: 26794455]
Katz KD, Cannon RD, Cook MD, Amaducci A, Day R, Enyart J, Burket G, Porter L, Roach T, Janssen J, Williams KE. Loperamide-Induced Torsades de Pointes: A Case Series. The Journal of emergency medicine. 2017 Sep:53(3):339-344. doi: 10.1016/j.jemermed.2017.04.027. Epub 2017 Jul 26 [PubMed PMID: 28755998]
Level 2 (mid-level) evidence